By Iain Gilbert
Date: Friday 10 Oct 2025
(Sharecast News) - Clinical-stage biotechnology firm Sareum said on Friday that it has discontinued its 16-week pre-clinical toxicology study for autoimmune and cancer candidate SDC-1801 after safety issues were flagged by a third-party provider.
By Josh White
Date: Thursday 29 May 2025
(Sharecast News) - Sareum announced the start of a programme of toxicology studies on Thursday, for its lead TYK2/JAK1 inhibitor - SDC-1801 - marking a key step toward phase two clinical development.
By Benjamin Chiou
Date: Tuesday 31 Dec 2024
(Sharecast News) - Autoimmune disease and cancer treatment developer Sareum has revealed that the commercial licence of its jointly developed SRA737 product has been terminated by a biopharma company in the US.
Currency | UK Pounds |
Share Price | 16.25p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 28.00p |
52 Week Low | 11.25p |
Volume | 313,923 |
Shares Issued | 138.07m |
Market Cap | £22.44m |
RiskGrade | 594 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth | ![]() |
---|
No dividends found |
Time | Volume / Share Price |
15:50 | 1,000 @ 16.32p |
15:49 | 40,429 @ 16.32p |
15:49 | 30,646 @ 16.32p |
15:24 | 5,547 @ 16.20p |
14:21 | 15,000 @ 16.50p |
You are here: research